Clinical Advisory Panel
GlyTherix draws upon the expertise of five internationally esteemed medical experts on its Clinical Advisory Panel
Dr Alan Harris (Chair)
NYU School MedicineLed clinical development and approval of octreotide – the peptide component of Lutathera.
Professor David Gillatt
Professor of Urological Oncology and Robotic Surgery and Director of Medical Services at Macquarie University Hospital.
Dr Neal Shore
Director of Carolina Urologic Research Centre and CMO Surgery/UrologyGenesis Healthcare.
Dr John Babich
President and CSO of Ratio Therapeutics. Leading radiochemist with proprietary chelator technologies.
Dr Elcin Zan
Weill Cornell Medicine dual board-certified radiologist specializing in Neuroradiology and Nuclear Medicine.
Dr Colin Hayward
Based in the USA Dr Hayward has over 25 years of global pharmaceutical, biotechnology and drug development experience.